STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial

AI Summary

An investigational combination of Eli Lilly’s Zepbound and an amylin drug produced significant weight loss in a mid-stage clinical trial. High discontinuation rates raised concerns about the combination’s tolerability.

An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.